Educational Archives - CX Symposium

The Top Cardiovascular News Stories of 2022!

[email protected]2023-01-02T03:57:22+00:00

What a year! We are taking a look back at the most viewed news stories. Check out these top stories and videos and make sure you haven’t missed any of 2022’s most-viewed news!

Remember – you can still claim up to 24 reciprocal EU/US CME credits for viewing CX 2022 and CX […]

The Top Cardiovascular News Stories of 2022![email protected]2023-01-02T03:57:22+00:00

Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018

cxsymposium2019-09-09T09:16:45+01:00

Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018
Ulf Teichgräber, Jena, Germany

Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018cxsymposium2019-09-09T09:16:45+01:00

EVAS is associated with a reduction in all-cause mortality

cxsymposium2019-09-09T09:19:47+01:00

EVAS is associated with a reduction in all-cause mortality
Marc Schermerhorn, Boston, United States

EVAS is associated with a reduction in all-cause mortalitycxsymposium2019-09-09T09:19:47+01:00

Podium 1st: Lutonix AV IDE interim 24 month update

cxsymposium2018-04-26T13:27:11+01:00

Podium 1st: Lutonix AV IDE interim 24 month update
Kate Steiner, Stevenage, United Kingdom

Podium 1st: Lutonix AV IDE interim 24 month updatecxsymposium2018-04-26T13:27:11+01:00